(MENAFN- Baystreet.ca) 10:01 AM EST - Innunoprecise Antibodies Ltd. : And LiteVax BV (Oss, the Netherlands ), today announced that they have initiated pre-clinical vaccine trials against SARS-CoV-2. Vaccine design was based on large sets of data obtained during the analysis of IPA's SARS-CoV-2 therapeutic programs. Using this information, ImmunoPrecise designed data-driven, well-defined SARS-CoV-2 spike protein variant vaccine candidates that were combined with a novel class of synthetic carbohydrate derivatives, designed to act as a vaccine adjuvant, with the final formulations aimed at high efficacy and low adverse effects. Innunoprecise Antibodies Ltd. shares V.IPA are trading up $0.08 at $2.45.
MENAFN2509202002120000ID1100857882
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.